(REGN) Regeneron Pharmaceuticals - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US75886F1075

Eye, Dermatology, Asthma, Cancer, Arthritis

Stock: Biotechnology
Age 34.8y

MCap 78,634m
Avg Vol 825K (638M USD)

Beta 0.559
Volatility 36.79%

EPS (Earnings per Share)

EPS CAGR: -44.12%
EPS Trend: -36.7%

Last SUE: -4.00
Qual. Beats: 0

Revenue

Rev. CAGR: -7.12%
Rev. Trend: 15.0%

Last SUE: 0.91
Qual. Beats: 2

Dividends

Dividend Yield	0.54%
Yield on Cost 5y	0.66%
Yield CAGR 5y	0.00%
Payout Consistency	100.0%
Payout Ratio	7.8%

Risk via 5d forecast
Volatility	36.8%
Value at Risk 5%th	55.7%
Relative Tail Risk	-7.94%

Reward TTM
Sharpe Ratio	0.26
Alpha	-7.12
CAGR/Max DD	0.01

Character TTM
Hurst Exponent	0.359
Beta	0.559
Beta Downside	0.328

Drawdowns 3y
Max DD	59.69%
Mean DD	21.34%
Median DD	9.94%

Description: REGN Regeneron Pharmaceuticals December 03, 2025

Regeneron Pharmaceuticals (NASDAQ: REGN) is a U.S. biotech firm that discovers, invents, develops, manufactures, and commercializes a broad portfolio of injectable medicines across ophthalmology, immunology, oncology, cardiovascular, infectious disease, and rare-disease markets. Its flagship products include EYLEA for retinal disorders, Dupixent for atopic dermatitis and asthma, Libtayo for cutaneous squamous-cell carcinoma, and the COVID-19 antibody cocktail REGEN-COV, among dozens of other specialty therapies.

As of FY 2023, Regeneron reported $13.3 billion in revenue, driven primarily by EYLEA (≈ $5 billion) and Dupixent (≈ $3 billion). The company reinvested roughly $3.1 billion in R&D, reflecting a pipeline of ~ 20 late-stage candidates and multiple CRISPR-gene-editing collaborations (e.g., Mammoth Biosciences). Key sector drivers that influence its outlook are the aging-population-induced demand for ophthalmic and cardiovascular drugs, the expanding market for biologics in immunology, and the industry-wide shift toward gene-editing platforms, which could materially affect future growth trajectories.

For a deeper quantitative dive, you might explore ValueRay’s analyst tools to assess Regeneron’s valuation dynamics.

Piotroski VR‑10 (Strict, 0-10) 7.0

Net Income (4.58b TTM) > 0 and > 6% of Revenue (6% = 854.9m TTM)

FCFTA 0.10 (>2.0%) and ΔFCFTA 1.32pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 95.14% (prev 113.2%; Δ -18.04pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.13 (>3.0%) and CFO 5.07b > Net Income 4.58b (YES >=105%, WARN >=100%)

Net Debt (199.1m) to EBITDA (5.71b) ratio: 0.03 <= 3.0 (WARN <= 3.5)

Current Ratio 4.06 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (107.2m) change vs 12m ago -7.75% (target <= -2.0% for YES)

Gross Margin 85.39% (prev 85.31%; Δ 0.08pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 36.72% (prev 36.98%; Δ -0.27pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 123.2 (EBITDA TTM 5.71b / Interest Expense TTM 42.1m) >= 6 (WARN >= 3)

Altman Z'' 9.96

(A) 0.34 = (Total Current Assets 17.98b - Total Current Liabilities 4.43b) / Total Assets 40.17b

(B) 0.87 = Retained Earnings (Balance) 35.05b / Total Assets 40.17b

warn (B) unusual magnitude: 0.87 — check mapping/units

(D) 3.81 = Book Value of Equity 35.11b / Total Liabilities 9.21b

Total Rating: 9.96 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 74.85

1. Piotroski 7.0pt

2. FCF Yield 5.70%

3. FCF Margin 29.16%

4. Debt/Equity 0.09

5. Debt/Ebitda 0.03

6. ROIC - WACC (= 5.72)%

7. RoE 15.31%

8. Rev. Trend 15.02%

9. EPS Trend -36.72%

What is the price of REGN shares?

As of January 18, 2026, the stock is trading at USD 733.04 with a total of 1,678,509 shares traded.
Over the past week, the price has changed by -7.97%, over one month by -1.78%, over three months by +28.95% and over the past year by +6.33%.

Is REGN a buy, sell or hold?

Regeneron Pharmaceuticals has received a consensus analysts rating of 4.28. Therefore, it is recommended to buy REGN.

Strong Buy: 14
Buy: 5
Hold: 5
Sell: 1
Strong Sell: 0

What are the forecasts/targets for the REGN price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	826	12.7%
Analysts Target Price	826	12.7%
ValueRay Target Price	763.6	4.2%

REGN Fundamental Data Overview January 17, 2026

P/E Trailing = 17.7918
P/E Forward = 16.8634
P/S = 5.519
P/B = 2.5188
P/EG = 1.411
Revenue TTM = 14.25b USD
EBIT TTM = 5.19b USD
EBITDA TTM = 5.71b USD
Long Term Debt = 1.99b USD (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = 2.71b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 199.1m USD (from netDebt column, last quarter)
Enterprise Value = 72.90b USD (78.63b + Debt 2.71b - CCE 8.44b)
Interest Coverage Ratio = 123.2 (Ebit TTM 5.19b / Interest Expense TTM 42.1m)
EV/FCF = 17.55x (Enterprise Value 72.90b / FCF TTM 4.15b)
FCF Yield = 5.70% (FCF TTM 4.15b / Enterprise Value 72.90b)
FCF Margin = 29.16% (FCF TTM 4.15b / Revenue TTM 14.25b)
Net Margin = 32.13% (Net Income TTM 4.58b / Revenue TTM 14.25b)
Gross Margin = 85.39% ((Revenue TTM 14.25b - Cost of Revenue TTM 2.08b) / Revenue TTM)
Gross Margin QoQ = 86.11% (prev 85.58%)
Tobins Q-Ratio = 1.81 (Enterprise Value 72.90b / Total Assets 40.17b)
Interest Expense / Debt = 0.71% (Interest Expense 19.3m / Debt 2.71b)
Taxrate = 17.20% (303.3m / 1.76b)
NOPAT = 4.29b (EBIT 5.19b * (1 - 17.20%))
Current Ratio = 4.06 (Total Current Assets 17.98b / Total Current Liabilities 4.43b)
Debt / Equity = 0.09 (Debt 2.71b / totalStockholderEquity, last quarter 30.96b)
Debt / EBITDA = 0.03 (Net Debt 199.1m / EBITDA 5.71b)
Debt / FCF = 0.05 (Net Debt 199.1m / FCF TTM 4.15b)
Total Stockholder Equity = 29.91b (last 4 quarters mean from totalStockholderEquity)
RoA = 11.80% (Net Income 4.58b / Total Assets 40.17b)
RoE = 15.31% (Net Income TTM 4.58b / Total Stockholder Equity 29.91b)
RoCE = 16.26% (EBIT 5.19b / Capital Employed (Equity 29.91b + L.T.Debt 1.99b))
RoIC = 13.47% (NOPAT 4.29b / Invested Capital 31.89b)
WACC = 7.74% (E(78.63b)/V(81.34b) * Re(7.99%) + D(2.71b)/V(81.34b) * Rd(0.71%) * (1-Tc(0.17)))
Discount Rate = 7.99% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -81.65 | Cagr: -2.94%
[DCF Debug] Terminal Value 76.49% ; FCFF base≈3.84b ; Y1≈3.26b ; Y5≈2.49b
Fair Price DCF = 459.6 (EV 47.67b - Net Debt 199.1m = Equity 47.47b / Shares 103.3m; r=7.74% [WACC]; 5y FCF grow -18.28% → 2.90% )
EPS Correlation: -36.72 | EPS CAGR: -44.12% | SUE: -4.0 | # QB: 0
Revenue Correlation: 15.02 | Revenue CAGR: -7.12% | SUE: 0.91 | # QB: 2
EPS next Quarter (2026-03-31): EPS=10.24 | Chg30d=-0.187 | Revisions Net=+2 | Analysts=11
EPS next Year (2026-12-31): EPS=39.56 | Chg30d=+1.199 | Revisions Net=+3 | Growth EPS=-3.1% | Growth Revenue=+7.9%

Additional Sources for REGN Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle